Helmy M. Siragy


  • Fellowship, The University of Texas Health Science Center at San Antonio
  • Fellowship, University of Virginia
  • Residency, University of Texas, Galveston
  • MD, Tanta University

Primary Appointment

  • Professor, Medicine- Endocrinology and Metabolism


Research Interest(s)

Endocrine hypertension, angiotensin receptors, renal paracrine hormones

Research Description

An international expert on subjects related to hypertension, Dr. Siragy was the first to discover that stimulation of angiotensin AT2 receptor leads to generation of nitric oxide. Siragy has authored more than 250 medical journal articles and abstracts, and numerous medical textbook chapters, including a chapter on the kidney and the renin angiotensin system in the Braunwald Atlas of Heart Diseases; a chapter on angiotensin and diabetic nephropathy in Harrison's on-line textbook of Medicine; and a chapter on the angiotensin receptor in Hypertension: A Companion to Brenner. Dr Siragy's primary research interests are in the areas of the renin-angiotensin system, cardiac ischemia, diabetic nephropathy and (Pro)Renin receptor.

Selected Publications

  • Quadri S, Siragy H. Regulation of (pro)renin receptor expression in mIMCD via the GSK-3β-NFAT5-SIRT-1 signaling pathway. American journal of physiology. Renal physiology. 2014;307(5): F593-600. PMID: 24990896
  • Huang J, Ledford K, Pitkin W, Russo L, Najjar S, Siragy H. Targeted deletion of murine CEACAM 1 activates PI3K-Akt signaling and contributes to the expression of (Pro)renin receptor via CREB family and NF-κB transcription factors. Hypertension. 2013;62(2): 317-23. PMID: 23734002 | PMCID: PMC3793251
  • Matavelli L, Huang J, Siragy H. In vivo regulation of renal expression of (pro)renin receptor by a low-sodium diet. American journal of physiology. Renal physiology. 2012;303(12): F1652-7. PMID: 23077099 | PMCID: PMC3532474
  • Matavelli L, Siragy H. Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats. Journal of cardiovascular pharmacology. 2012;61(1): 17-22. PMID: 23011470 | PMCID: PMC3538933
  • Waeber B, Siragy H. Mild hypertension: to treat or not to treat? Current hypertension reports. 2012;15(1): 1-2. PMID: 23152161
  • A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors. Vascular health and risk management. 2011;7 297-313. PMID: 21633727 | PMCID: PMC3104607
  • Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations. Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2011;25(1): 87-97. PMID: 21213120
  • To ACCELERATE hypertension control. Current hypertension reports. 2011;13(4): 259-61. PMID: 21494776
  • Abadir P, Walston J, Carey R, Siragy H. Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production. Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 2011;31(6): 471-4. PMID: 21288138 | PMCID: PMC3104285
  • Huang J, Matavelli L, Siragy H. Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade. Clinical and experimental pharmacology & physiology. 2011;38(4): 215-21. PMID: 21265872 | PMCID: PMC3077929
  • Huang J, Siragy H. Sodium depletion enhances renal expression of (pro)renin receptor via cyclic GMP-protein kinase G signaling pathway. Hypertension. 2011;59(2): 317-23. PMID: 22203739 | PMCID: PMC3266459
  • Matavelli L, Huang J, Siragy H. Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats. Journal of cardiovascular pharmacology. 2011;59(3): 281-7. PMID: 22075749 | PMCID: PMC3296909